LAS VEGAS--(BUSINESS WIRE)--May 23, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV - News): Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, it has filed a new provisional U.S. patent application to support its original application, and add additional claims, for its cardiovascular drug SP-1000 for the prevention and treatment of cardiovascular disease.
